Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Jaffee

Showing results (131-140 of 291) with videos related to

Pageof 30
Sort By:
The Journal of Experimental Medicine|August 4, 2004
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patientsAmy Morck Thomas, Lynn M Santarsiero, Eric R Lutz, et al.
JCI Insight|July 13, 2018
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinomaAlexander C Hopkins, Mark Yarchoan, Jennifer N Durham, et al.
Cancer Immunology Research|January 27, 2026
Computational modeling of cellular influence delineates functionally relevant and distinct cellular neighborhoods in primary and metastatic pancreatic ductal adenocarcinomaYeonju Cho, Jae W Lee, Sarah M Shin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 9, 2013
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancerDung T Le, Eric Lutz, Jennifer N Uram, et al.
JCI Insight|March 22, 2019
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersMark Yarchoan, Lee A Albacker, Alexander C Hopkins, et al.
Cancer Research|July 10, 2012
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancerQingfei Wang, Shau-Hsuan Li, Hai Wang, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 25, 2007
Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus settingTomoharu Miyashita, Furhawn A Shah, Guy Marti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
Characterization of the Immune Microenvironment in Hepatocellular CarcinomaMark Yarchoan, Dongmei Xing, Lan Luan, et al.
Cancer Immunology Research|January 16, 2019
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer ActivityHayley S Ma, Bibhav Poudel, Evanthia Roussos Torres, et al.
Annals of Surgical Oncology|June 20, 2014
A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancerLei Zheng, Barish H Edil, Kevin C Soares, et al.
Pageof 30

Showing results (131-140 of 291) with videos related to

Sort By:
Pageof 30
The Journal of Experimental Medicine|August 4, 2004
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patientsAmy Morck Thomas, Lynn M Santarsiero, Eric R Lutz, et al.
JCI Insight|July 13, 2018
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinomaAlexander C Hopkins, Mark Yarchoan, Jennifer N Durham, et al.
Cancer Immunology Research|January 27, 2026
Computational modeling of cellular influence delineates functionally relevant and distinct cellular neighborhoods in primary and metastatic pancreatic ductal adenocarcinomaYeonju Cho, Jae W Lee, Sarah M Shin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 9, 2013
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancerDung T Le, Eric Lutz, Jennifer N Uram, et al.
JCI Insight|March 22, 2019
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersMark Yarchoan, Lee A Albacker, Alexander C Hopkins, et al.
Cancer Research|July 10, 2012
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancerQingfei Wang, Shau-Hsuan Li, Hai Wang, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 25, 2007
Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus settingTomoharu Miyashita, Furhawn A Shah, Guy Marti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
Characterization of the Immune Microenvironment in Hepatocellular CarcinomaMark Yarchoan, Dongmei Xing, Lan Luan, et al.
Cancer Immunology Research|January 16, 2019
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer ActivityHayley S Ma, Bibhav Poudel, Evanthia Roussos Torres, et al.
Annals of Surgical Oncology|June 20, 2014
A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancerLei Zheng, Barish H Edil, Kevin C Soares, et al.
Pageof 30